Sam Isaly, the legendary manager of Eaton Vance Worldwide Health Sciences Fund, has overdosed on many large drug companies this year. But he's still a big fan of Swiss drug-maker Novartis.

WHEN YOU'RE A LEGEND, you can afford to be candid about your mistakes.

And this year, Sam Isaly, the manager of the Eaton Vance Worldwide Health Sciences Fund, isn't pulling punches on his own performance. So far this year, the fund has gained only 2.9%, four percentage points less than the average health-care mutual fund tracked by Morningstar.

"In the last year, I'm not impressed with what we've done,'' he says. Luckily...